Nexus Pharmaceuticals Receives Patent for EMERPHED® Ready-To-Use Ephedrine Sulfate Injection

Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, has received a patent covering applications of EMERPHED Ready-To-Use Ephedrine Sulfate Injection, the first FDA-approved premixed ephedrine in a ready-to-use 50 mg/10 mL vial.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, August 17, 2021
Information
Tags: 
FDA, Pharmaceutical, Health, Clinical Trials, Nexus, Journal, Anesthesia, Blood pressure, Technology, Vomiting, Medical college, Sulfate, Trial of the century, Tachycardia, MCW, Nausea, Patent, Drug, Multimedia, Medication, Risk, Hypotension, FDA, Tachyphylaxis, Pharmacy, Medical College of Wisconsin, USPTO, Pharmaceutical industry, EMERPHED® Ready-To-Use Ephedrine Sulfate Injection, Nexus Pharmaceuticals, Inc., EMERPHED® READY-TO-USE EPHEDRINE SULFATE INJECTION, NEXUS PHARMACEUTICALS, INC.
Geotags: 
United States, Illinois, US, WISCONSIN
⚠ generated by AI ↴
Organisation: 
EMERPHED® READY-TO-USE EPHEDRINE SULFATE INJECTION, NEXUS PHARMACEUTICALS, INC.
Summary
Key Points: 
  • Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, has received a patent covering applications of EMERPHED Ready-To-Use Ephedrine Sulfate Injection, the first FDA-approved premixed ephedrine in a ready-to-use 50 mg/10 mL vial.
  • The United States Patent and Trademark Office (USPTO) issued the patent, U.S. Patent No.
  • View the full release here: https://www.businesswire.com/news/home/20210817005708/en/
    EMERPHED Ready-To-Use Ephedrine Sulfate Injection, the first FDA-approved premixed ephedrine, was launched by Nexus Pharmaceuticals in 2020.
  • (Photo: Business Wire)
    We are very proud of the intellectual property that was created during the development of EMERPHED, said Shahid Ahmed, Chief Scientific Officer of Nexus Pharmaceuticals.


Nexus Pharmaceuticals, Inc., a U.S.-based healthcare company and domestic pharmaceutical manufacturer, has received a patent covering applications of EMERPHED® Ready-To-Use Ephedrine Sulfate Injection, the first FDA-approved premixed ephedrine in a ready-to-use 50 mg/10 mL vial. The United States Patent and Trademark Office (USPTO) issued the patent, U.S. Patent No. 11,090,278, on August 17, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210817005708/en/

EMERPHED® Ready-To-Use Ephedrine Sulfate Injection, the first FDA-approved premixed ephedrine, was launched by Nexus Pharmaceuticals in 2020. (Photo: Business Wire)

EMERPHED® Ready-To-Use Ephedrine Sulfate Injection, the first FDA-approved premixed ephedrine, was launched by Nexus Pharmaceuticals in 2020. (Photo: Business Wire)

“We are very proud of the intellectual property that was created during the development of EMERPHED®,” said Shahid Ahmed, Chief Scientific Officer of Nexus Pharmaceuticals. “The granting of this patent is the culmination of many years of scientific development and the hard work of our dedicated team.”

In February 2021, the Medical College of Wisconsin published a clinical study showing the reduction of potential risk for error and ease of use of EMERPHED®as compared to commercially used concentrated ephedrine. MCW published a press release with their findings in February 2021, and the clinical study was published in the Journal of Pharmaceutical Science and Technology in June 2021.

About EMERPHED® Ready-To-Use Ephedrine Sulfate Injection

INDICATIONS AND USAGE

Ephedrine Sulfate injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

WARNINGS AND PRECAUTIONS

Emerphed can cause pressor effects with concomitant use with oxytocic drugs. Can also cause tachyphylaxis with repeated administration of ephedrine.

CONTRAINDICATIONS

None

OVERDOSAGE

Overdose of Emerphed can cause a rapid rise in blood pressure. In the case of an overdose, careful monitoring of blood pressure is recommended. If blood pressure continues to rise to an unacceptable level, parenteral antihypertensive agents can be administered at the discretion of the clinician.

ADVERSE REACTIONS

Most common adverse reactions during treatment: nausea, vomiting, and tachycardia. To report SUSPECTED ADVERSE REACTIONS, contact Nexus Pharmaceuticals at (855) 642-2594 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For full prescribing information, please see the following link.

About Nexus Pharmaceuticals, Inc.

Nexus Pharmaceuticals, Inc. is a US-based, woman-led, minority-owned healthcare company and certified diverse supplier, specializing in innovative processes to make difficult-to- manufacture specialty and generic injectables that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. For more information about Nexus Pharmaceuticals, including our new state-of-the-art Wisconsin manufacturing facility, please visit www.nexuspharma.net.

Copyright: 
Copyright Business Wire 2021